Teleflex Incorporated (NYSE:TFX) Receives Average Recommendation of “Moderate Buy” from Brokerages

Teleflex Incorporated (NYSE:TFX) has been given an average recommendation of “Moderate Buy” by the eight analysts that are currently covering the company, Marketbeat reports. Two research analysts have rated the stock with a hold rating and six have issued a buy rating on the company. The average twelve-month target price among brokerages that have covered the stock in the last year is $260.14.

A number of equities research analysts have recently weighed in on the stock. Truist Financial cut their target price on shares of Teleflex from $240.00 to $219.00 and set a “hold” rating on the stock in a research note on Friday, May 3rd. Piper Sandler raised shares of Teleflex from a “neutral” rating to an “overweight” rating and lifted their target price for the company from $205.00 to $245.00 in a research note on Monday. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Teleflex in a research note on Friday, May 3rd.

Teleflex Price Performance

TFX stock opened at $211.11 on Wednesday. The firm’s 50-day moving average price is $207.93 and its two-hundred day moving average price is $225.41. Teleflex has a 12-month low of $177.63 and a 12-month high of $262.97. The stock has a market capitalization of $9.94 billion, a price-to-earnings ratio of 33.89, a PEG ratio of 2.04 and a beta of 1.13. The company has a current ratio of 2.51, a quick ratio of 1.41 and a debt-to-equity ratio of 0.37.

Teleflex (NYSE:TFX) last announced its earnings results on Thursday, May 2nd. The medical technology company reported $3.21 earnings per share for the quarter, beating analysts’ consensus estimates of $3.07 by $0.14. The firm had revenue of $737.80 million for the quarter, compared to analyst estimates of $726.85 million. Teleflex had a net margin of 9.82% and a return on equity of 14.78%. The company’s revenue for the quarter was up 3.8% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $3.09 EPS. As a group, equities analysts predict that Teleflex will post 13.75 earnings per share for the current year.

Teleflex Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Friday, June 14th. Investors of record on Wednesday, May 15th were paid a dividend of $0.34 per share. This represents a $1.36 annualized dividend and a yield of 0.64%. The ex-dividend date was Tuesday, May 14th. Teleflex’s payout ratio is currently 21.83%.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Kentucky Retirement Systems lifted its stake in shares of Teleflex by 1.1% in the fourth quarter. Kentucky Retirement Systems now owns 3,760 shares of the medical technology company’s stock worth $938,000 after buying an additional 42 shares in the last quarter. Venturi Wealth Management LLC lifted its stake in shares of Teleflex by 33.3% in the fourth quarter. Venturi Wealth Management LLC now owns 184 shares of the medical technology company’s stock worth $46,000 after buying an additional 46 shares in the last quarter. KBC Group NV lifted its stake in shares of Teleflex by 1.8% in the fourth quarter. KBC Group NV now owns 3,173 shares of the medical technology company’s stock worth $791,000 after buying an additional 55 shares in the last quarter. Lindbrook Capital LLC lifted its stake in shares of Teleflex by 75.3% in the fourth quarter. Lindbrook Capital LLC now owns 135 shares of the medical technology company’s stock worth $34,000 after buying an additional 58 shares in the last quarter. Finally, Empirical Finance LLC lifted its stake in shares of Teleflex by 3.9% in the first quarter. Empirical Finance LLC now owns 1,564 shares of the medical technology company’s stock worth $354,000 after buying an additional 58 shares in the last quarter. Institutional investors own 95.62% of the company’s stock.

Teleflex Company Profile

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site.